NasdaqCM - Delayed Quote USD

Adagio Medical Holdings, Inc. (ADGM)

Compare
2.9000 +0.2800 (+10.69%)
At close: October 25 at 4:00 PM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
Total Revenue
266.0000
300.0000
189.0000
270.0000
Cost of Revenue
1,530.0000
1,306.0000
875.0000
1,158.0000
Gross Profit
-1,264.0000
-1,006.0000
-686.0000
-888.0000
Operating Expense
28,839.0000
26,936.0000
23,227.0000
19,757.0000
Operating Income
-30,103.0000
-27,942.0000
-23,913.0000
-20,645.0000
Net Non Operating Interest Income Expense
-2,177.0000
-1,656.0000
-98.0000
3.0000
Other Income Expense
-4,608.0000
-8,548.0000
338.0000
704.0000
Pretax Income
-36,888.0000
-38,146.0000
-23,673.0000
-19,938.0000
Net Income Common Stockholders
-36,888.0000
-38,146.0000
-23,673.0000
-19,938.0000
Diluted NI Available to Com Stockholders
-36,888.0000
-38,146.0000
-23,673.0000
-19,938.0000
Basic EPS
-2.76
-2.85
-1.77
-1.49
Diluted EPS
-2.76
-2.85
-1.77
-1.49
Basic Average Shares
13,387.6360
13,387.6360
13,387.6360
13,387.6360
Diluted Average Shares
13,387.6360
13,387.6360
13,387.6360
13,387.6360
Total Operating Income as Reported
-30,103.0000
-27,942.0000
-23,913.0000
-20,645.0000
Total Expenses
30,369.0000
28,242.0000
24,102.0000
20,915.0000
Net Income from Continuing & Discontinued Operation
-36,888.0000
-38,146.0000
-23,673.0000
-19,938.0000
Normalized Income
-32,347.0000
-29,618.0000
-23,673.0000
-20,682.0000
Interest Income
3.0000
3.0000
39.0000
3.0000
Interest Expense
2,180.0000
1,659.0000
137.0000
--
Net Interest Income
-2,177.0000
-1,656.0000
-98.0000
3.0000
EBIT
-34,708.0000
-36,487.0000
-23,536.0000
-19,938.0000
EBITDA
-33,970.0000
-35,955.0000
-23,041.0000
-19,602.0000
Reconciled Cost of Revenue
1,530.0000
1,306.0000
875.0000
1,158.0000
Reconciled Depreciation
738.0000
532.0000
495.0000
336.0000
Net Income from Continuing Operation Net Minority Interest
-36,888.0000
-38,146.0000
-23,673.0000
-19,938.0000
Total Unusual Items Excluding Goodwill
-4,541.0000
-8,528.0000
--
744.0000
Total Unusual Items
-4,541.0000
-8,528.0000
--
744.0000
Normalized EBITDA
-29,429.0000
-27,427.0000
-23,041.0000
-20,346.0000
12/31/2021 - 8/2/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers